STOCK TITAN
  1. Home
  2. News
  3. RYZB

RayzeBio, Inc. - RYZB STOCK NEWS

Welcome to our dedicated page for RayzeBio news (Ticker: RYZB), a resource for investors and traders seeking the latest updates and insights on RayzeBio stock.

RayzeBio, Inc. (NASDAQ: RYZB) is at the forefront of developing innovative radiopharmaceutical therapeutics aimed at treating various cancers. The company's lead asset, RYZ101, is the first Actinium-225 based treatment currently in a Phase 3 clinical trial. This pioneering treatment is part of RayzeBio's broader mission to bring novel radiopharmaceuticals to market, much like antibody drug conjugates have transformed cancer therapy.

In 2023, RayzeBio achieved significant milestones, including clinical advancements and corporate achievements. The company is on track to file an Investigational New Drug (IND) application in the first half of 2024 for a new candidate focused on liver cancer.

RayzeBio's recent IPO in September 2023 was oversubscribed, boosting its financial strength and enabling full investment in its key initiatives. The company has built a vertically integrated business model to support its robust product pipeline, development capabilities, and manufacturing infrastructure. This strategic approach positions RayzeBio as a potential industry leader in the application of radiopharmaceutical therapeutics.

The company's efforts are supported by a strong balance sheet, allowing it to advance its programs without financial constraints. With a dedicated team and strategic partnerships, RayzeBio is committed to making significant strides in cancer treatment, benefiting patients worldwide.

RayzeBio's management emphasizes transparency and forward-looking strategies. While the company's ambitions are high, they acknowledge the inherent risks and uncertainties in drug development, regulatory approvals, and market dynamics. However, their confidence in their pipeline and strategic direction remains steadfast.

For more information and the latest updates on RayzeBio, Inc., visit their official website or contact their corporate office.

News

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

Rhea-AI Summary
Bristol Myers Squibb (BMY) completes the acquisition of RayzeBio, Inc. (RYZB) to strengthen its oncology pipeline with radiopharmaceutical therapeutics. The acquisition includes RYZ101, a promising RPT targeting somatostatin receptor 2 in GEP-NETs and ES-SCLC. Bristol Myers Squibb plans to leverage RayzeBio's IND engine and manufacturing facility to accelerate preclinical and clinical programs, offering growth opportunities in the coming years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

Rhea-AI Summary
Bristol Myers Squibb (BMY) has completed the acquisition of RayzeBio, Inc. for approximately $4.1 billion, with 86% of RayzeBio's shares tendered. The transaction is expected to close on February 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

Rhea-AI Summary
Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announce the expiration of the waiting period under the HSR Act for BMY's tender offer to acquire RYZB for $62.50 per share in cash, totaling $4.1 billion. The transaction remains subject to the tender of a majority of RYZB's outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire RayzeBio (RYZB) for $4.1 Billion, Expanding Oncology Portfolio and Radiopharmaceutical Platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
RayzeBio, Inc. (Nasdaq: RYZB) reported financial results for Q3 2023 and provided updates on clinical trials and corporate milestones. Recent highlights include RYZ101's Phase 3 clinical trial progress and a confirmed objective response rate of 29%. RYZ801 and RYZ811 IND filing for HCC is expected in 1H 2024. The company's manufacturing facility is on track for completion by the end of 2023, and it completed a $357 million IPO. The cash position as of September 30, 2023, was $540.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
earnings
-
News

RayzeBio to Participate in Upcoming Investor Conferences in November 2023

Rhea-AI Summary
RayzeBio, Inc. (Nasdaq: RYZB) will be participating in several investor conferences in November 2023 to discuss their innovative radiopharmaceutical pipeline for cancer treatment. The conferences include Truist Securities BioPharma Symposium, Jefferies London Healthcare Conference, and Evercore ISI HealthCONx Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
conferences
News

RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

Rhea-AI Summary
RayzeBio, Inc. has announced the appointment of Tim Van Hauwermeiren to its board of directors. Tim, the co-founder and CEO of argenx, brings extensive experience in general management and business development. RayzeBio aims to transform the oncology treatment landscape through targeted radiopharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
management
-
News

FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs

Rhea-AI Summary
RayzeBio's RYZ101 selected by FDA for CMC Development and Readiness Pilot program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
-
News

RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress

Rhea-AI Summary
RayzeBio to present interim safety and efficacy data from Phase 1b trial at ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
News

RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary
RayzeBio, Inc. closes upsized $358 million IPO, selling 19,869,240 shares of common stock at $18.00 per share. Gross proceeds to RayzeBio were approximately $336.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
IPO offering

FAQ

What is the market cap of RayzeBio (RYZB)?

The market cap of RayzeBio (RYZB) is approximately 3.8B.

What is RayzeBio, Inc.?

RayzeBio, Inc. is a biopharmaceutical company focused on developing innovative radiopharmaceutical therapies for cancer.

What is RYZ101?

RYZ101 is RayzeBio's lead asset, an Actinium-225 based radiopharmaceutical currently in Phase 3 clinical trials for cancer treatment.

What recent milestones has RayzeBio achieved?

In 2023, RayzeBio made significant progress, including clinical advancements and filing for an IND for a liver cancer drug candidate.

What makes RayzeBio unique?

RayzeBio is building a vertically integrated model to support a robust product pipeline, aiming to become a leader in radiopharmaceutical therapeutics.

What was significant about RayzeBio's IPO in September 2023?

RayzeBio's IPO was oversubscribed, which provided a strong financial foundation to invest in its initiatives and support its growth.

When does RayzeBio plan to file an IND for their next candidate?

RayzeBio plans to file an IND in the first half of 2024 for their next drug candidate aimed at treating liver cancer.

What are the company's future plans?

RayzeBio aims to advance its pipeline of radiopharmaceuticals, complete clinical trials, and bring innovative cancer treatments to market.

How is RayzeBio funded for its operations?

RayzeBio's successful IPO and strong balance sheet ensure sufficient capital resources to fund its anticipated operations and clinical trials.

Who leads RayzeBio?

RayzeBio is led by President and CEO Ken Song, M.D., alongside a dedicated team of professionals in the biotech industry.

What should investors know about RayzeBio?

Investors should note RayzeBio's strategic investments, innovative pipeline, and potential to lead in the radiopharmaceutical sector for cancer treatments.

Stock RYZB logo
RayzeBio, Inc.

NYSE:RYZB

RYZB Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

RYZB Stock Data

3.75B
44.15M
9.69%
89.71%
1.41%
Biotechnology
Healthcare
Link
United States
San Diego